OTCMKTS:ELTP Elite Pharmaceuticals (ELTP) Stock Price, News & Analysis $0.64 +0.00 (+0.39%) As of 10/3/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisChartEarningsHeadlinesSEC FilingsShort InterestBuy This Stock About Elite Pharmaceuticals Stock (OTCMKTS:ELTP) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Elite Pharmaceuticals alerts:Sign Up Key Stats Today's Range$0.62▼$0.6750-Day Range$0.49▼$0.7152-Week Range$0.27▼$0.82Volume560,515 shsAverage Volume1.10 million shsMarket Capitalization$686.95 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company Overview Elite Pharmaceuticals, Inc. is a U.S.-based specialty pharmaceutical company that acquires, develops and markets both branded and generic pharmaceutical products. Headquartered in Houston, Texas, the company focuses on complex dosage forms—including injectables, sterile formulations and oncology therapies—and seeks to address unmet medical needs through advanced drug delivery technologies. Its product portfolio spans therapeutic areas such as pain management, oncology and cardiovascular care. Since its founding in 2007, Elite Pharmaceuticals has pursued strategic partnerships and licensing agreements to expand its pipeline and manufacturing capabilities. The company collaborates with contract manufacturing organizations and leverages distribution networks to supply products to wholesalers, hospitals and healthcare providers across the United States. Through these alliances, Elite Pharmaceuticals aims to streamline supply chains and enhance product availability for its key markets. Specific information on the company’s leadership team and key historical milestones is limited in publicly available sources. Industry records indicate the management group brings experience in pharmaceutical sourcing, regulatory affairs and product development. Elite Pharmaceuticals continues to explore opportunities for organic growth, business development and potential acquisitions, positioning itself to capitalize on innovation within the specialty pharmaceutical sector.AI Generated. May Contain Errors. Read More Elite Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks22nd Percentile Overall ScoreELTP MarketRank™: Elite Pharmaceuticals scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for Elite Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Elite Pharmaceuticals is -64.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Elite Pharmaceuticals is -64.00, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioElite Pharmaceuticals has a P/B Ratio of 12.80. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Elite Pharmaceuticals' valuation and earnings. Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.21% of the outstanding shares of Elite Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverElite Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elite Pharmaceuticals has recently decreased by 12.34%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldElite Pharmaceuticals does not currently pay a dividend.Dividend GrowthElite Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.21% of the outstanding shares of Elite Pharmaceuticals have been sold short.Short Interest Ratio / Days to CoverElite Pharmaceuticals has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Elite Pharmaceuticals has recently decreased by 12.34%, indicating that investor sentiment is improving significantly. News and Social Media3.3 / 5News Sentiment0.89 News SentimentElite Pharmaceuticals has a news sentiment score of 0.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.53 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Elite Pharmaceuticals this week, compared to 0 articles on an average week.Search Interest11 people have searched for ELTP on MarketBeat in the last 30 days. This is an increase of 1,000% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Elite Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Elite Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders14.42% of the stock of Elite Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 0.01% of the stock of Elite Pharmaceuticals is held by institutions.Read more about Elite Pharmaceuticals' insider trading history. Receive ELTP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Elite Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ELTP Stock News HeadlinesElite Pharmaceuticals, Inc. (OTC:ELTP) Q4 2025 Earnings Call TranscriptJuly 3, 2025 | msn.comElite Pharmaceuticals Inc (ELTP) Q4 2025 Earnings Call Highlights: Revenue Surge Amidst ...July 2, 2025 | finance.yahoo.comURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.October 4 at 2:00 AM | StockEarnings (Ad)Elite Pharmaceuticals, Inc. (ELTP) Q4 2025 Earnings Call TranscriptJuly 1, 2025 | seekingalpha.comElite Pharmaceuticals, Inc. (ELTP) - Yahoo FinanceJune 26, 2025 | finance.yahoo.comElite Pharmaceuticals, Inc.: Elite Pharmaceuticals Announces Commercial Launch of Generic Vyvanse(R)December 26, 2024 | finanznachrichten.deElite Pharmaceuticals Gains FDA Approval for Generic VyvanseNovember 19, 2024 | markets.businessinsider.comElite Pharmaceuticals, Inc. (PNK:ELTP) Q2 2025 Earnings Call TranscriptNovember 18, 2024 | msn.comSee More Headlines ELTP Stock Analysis - Frequently Asked Questions How have ELTP shares performed this year? Elite Pharmaceuticals' stock was trading at $0.5411 at the beginning of 2025. Since then, ELTP shares have increased by 18.3% and is now trading at $0.64. How were Elite Pharmaceuticals' earnings last quarter? Elite Pharmaceuticals Inc. (OTCMKTS:ELTP) announced its quarterly earnings data on Thursday, August, 14th. The specialty pharmaceutical company reported ($0.01) earnings per share (EPS) for the quarter. The specialty pharmaceutical company had revenue of $40.21 million for the quarter. Elite Pharmaceuticals had a negative net margin of 10.26% and a negative trailing twelve-month return on equity of 9.88%. Read the conference call transcript. How do I buy shares of Elite Pharmaceuticals? Shares of ELTP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Elite Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Elite Pharmaceuticals investors own include Research Frontiers (REFR), Co-Diagnostics (CODX), Novavax (NVAX), FuelCell Energy (FCEL), Onconova Therapeutics (ONTX), iBio (IBIO) and Inovio Pharmaceuticals (INO). Company Calendar Last Earnings8/14/2025Today10/04/2025Next Earnings (Estimated)11/13/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeOTCMKTS SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolOTCMKTS:ELTP CIK1053369 Webwww.elitepharma.com Phone(201) 750-2646Fax201-750-2755Employees40Year FoundedN/AProfitability EPS (Trailing Twelve Months)($0.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$4.32 million Net Margins-10.26% Pretax Margin-1.39% Return on Equity-9.88% Return on Assets-4.72% Debt Debt-to-Equity Ratio0.09 Current Ratio7.23 Quick Ratio5.44 Sales & Book Value Annual Sales$84.04 million Price / Sales8.17 Cash Flow$0.02 per share Price / Cash Flow37.16 Book Value$0.05 per share Price / Book12.80Miscellaneous Outstanding Shares1,073,363,000Free Float918,584,000Market Cap$686.95 million OptionableNot Optionable Beta0.15 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (OTCMKTS:ELTP) was last updated on 10/4/2025 by MarketBeat.com Staff From Our PartnersNvidia Times 1,000,000Nvidia’s latest AI chip is a $25,000 powerhouse — with 80 billion transistors and the ability to perform 60 tr...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredGold surges past $3,600 … but this has beat gold by 1,000xGold has surged past $3,600 an ounce — up 45% in the past year — but one veteran metals analyst says the real ...Weiss Ratings | SponsoredIs Nvidia about to Trigger Another 150X Opportunity?Nvidia gave investors a chance to make more than 150 times their money with its AI chips, known as graphics pr...InvestorPlace | SponsoredMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Elite Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Elite Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.